Pfizer (NYSE: PFE) has announced positive results from a late-stage clinical trial for its antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) in combination with lenalidomide and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The study successfully met its primary endpoint, demonstrating an improvement in overall survival (OS) compared to the placebo plus lenalidomide and rituximab. Additionally, the trial achieved its secondary endpoints, which included progression-free survival (PFS) and overall response rate (ORR).
The safety and tolerability profiles of Adcetris in this trial were found to be consistent with those observed in previous studies. Adcetris currently has several approvals for the treatment of classical Hodgkin lymphoma (cHL), CD30-expressing peripheral T-cell lymphomas (PTCL), and CD30-expressing mycosis fungoides (MF).
Following these positive results, Pfizer plans to submit the data to regulatory authorities for further consideration.- Flcube.com
